B2 High-Intermediate US 443 Folder Collection
After playing the video, you can click or select the word to look it up in the dictionary.
Loading...
Report Subtitle Errors
This episode was filmed on May 29th, 2020.
If we have more recent episodes on the COVID-19 pandemic,
we'll include them in the description.
[♪ INTRO]
Researchers have been working on vaccine candidates for COVID-19
for months now.
Some of their work looks like traditional vaccine development,
albeit on a super sped up timeline.
But other research groups are trying some more creative approaches
to therapy... including ones that involve directly editing our genes.
This is known as gene therapy, and it's not as outlandish
as you might be thinking.
The outlandish part is that viruses are one of our primary tools
for gene therapy -- meaning we might be able to solve
our current virus problem… with a virus.
However, this approach comes with some uncertainty
and a significant price tag, so it's hardly a sure thing.
Here's how it might work.
The goal of a vaccine is to safely expose your immune system
to antigens derived from an infectious agent like a virus.
After vaccination, our bodies recognize this antigen
and know how to defend against it for a period of time.
That might mean exposing our bodies to a weakened
or inactivated form of a virus or bacterium so that our immune systems
can produce antibodies against it.
But there are plenty of other ways we can end up with immunity.
For example, some doctors are already using convalescent plasma
from recovered patients to transfer their antibodies to patients
who are critically ill.
But that's still in the testing stages.
Some of the vaccine candidates making swift progress
in clinical trials are based on the nucleic acids DNA and RNA.
The idea is to teach our cells to make viral antigens and to show them
to our immune system -- rather than bundling
the antigens themselves in a shot.
One hurdle to this idea is getting that genetic code into cells.
RNA, in particular, can get broken down pretty quickly in our bodies.
But the concept is solid: teach cells to make a specific part
of the virus -- like the spike protein, which SARS-CoV-2
uses to invade our cells.
So rather than inject patients with just the code,
another approach is more akin to fighting fire with fire.
Or a virus with a virus.
After all, viruses are really efficient at injecting genetic material
into host cells.
It's what they do -- they're really just little nucleic acid
delivery packets, with instructions for making more packets.
And we can reprogram those instructions.
So they're actually perfect if we want to introduce
genetic instructions into a cell.
But we need a virus that won't also make us sick, which is why
adeno-associated viruses, or AAVs, are the DNA vehicle of choice.
AAVs are little viruses that don't cause disease,
further genetically engineered to deliver their payload
without making more of themselves.
They've already been used in the past in efforts
against other coronaviruses.
Different AAVs tend to infiltrate different tissues,
and since COVID-19 affects the lungs, we'd need to find an AAV
that can get to our airway.
Some of the AAVs scientists have tested were able to get
into human respiratory cells in culture, but they haven't been tested
in actual humans yet.
And since an AAV is just a tiny DNA delivery unit, we could swap out
different sequences and test them all very quickly.
AAV-based gene therapy for other diseases has already been approved
by the US Food and Drug Administration, which could speed
implementation of a version of this therapy for COVID,
at least according to some.
The potential downside is that this style of gene therapy
permanently edits cells.
Not as permanently as you might be thinking.
It wouldn't target our germ cells, meaning we wouldn't pass
this DNA down to our kids.
We don't yet know all of the cell types we would need to target,
but the changes probably wouldn't stay with us for a lifetime.
Which means any kind of AAV-based therapy we develop for SARS-CoV-2
would only be a temporary fix.
But it might offer us some level of protection while we're
waiting on a more permanent vaccine.
But we can't rule out other long-term side effects
from directly tinkering with our DNA, even if it seems like
it should be safe based on what we know.
On top of all that, there's the cost.
Since the currently approved AAV-based drugs treat extremely rare
genetic diseases, they come with an inflated price tag.
But since an AAV for COVID-19 would be a much larger market,
the cost would hopefully be lower.
Now, will gene therapy for the novel coronavirus ever actually be a thing?
We have some good news on that front.
Researchers in Massachusetts recently announced plans
for a COVID vaccine clinical trial using AAVs.
They're in the preclinical trials right now, and if all goes well,
they'll move into human trials later this year.
Which means if we do ever see AAV therapy, it will still be a while.
But it's definitely one of the more creative efforts out there
-- and we need to try everything we've got.
Thanks for watching this episode of SciShow, and thanks as always
to our amazing patrons.
Patrons not only make it possible for us to make free videos
for everyone -- they also have access to cool behind-the-scenes perks!
If you want to get involved, check out patreon.com/scishow.
[♪ OUTRO]
    You must  Log in  to get the function.
Tip: Click on the article or the word in the subtitle to get translation quickly!

Loading…

How to Fight COVID-19... with a Virus

443 Folder Collection
ally.chang published on June 15, 2020
More Recommended Videos
  1. 1. Search word

    Select word on the caption to look it up in the dictionary!

  2. 2. Repeat single sentence

    Repeat the same sentence to enhance listening ability

  3. 3. Shortcut

    Shortcut!

  4. 4. Close caption

    Close the English caption

  5. 5. Embed

    Embed the video to your blog

  6. 6. Unfold

    Hide right panel

  1. Listening Quiz

    Listening Quiz!

  1. Click to open your notebook

  1. UrbanDictionary 俚語字典整合查詢。一般字典查詢不到你滿意的解譯,不妨使用「俚語字典」,或許會讓你有滿意的答案喔